Gland Pharma Q1 FY27 Result: Net Profit Surges 47% YoY; CDMO Business Drives 50% of Revenues Gland Pharma reported a strong financial performance for the April-June quarter (Q1 FY27), with consolidated net profit rising 47% year-on-year to ₹317 crore. This marks a significant increase from the ₹215 crore recorded in the same period of the previous fiscal year. The company’s revenue from operations grew 19.5% to ₹1,800 crore, driven by robust performance in key markets. The US market was the primary growth driver, with revenue increasing 32% YoY to ₹981 crore. Europe also contributed to the growth, recording a 20% rise to ₹395 crore. Meanwhile, the India business saw a 12% year-on-year increase to ₹67 crore, while the rest of the world segment grew 2% to ₹304 crore. However, revenue from Canada, Australia, and New Zealand declined 28% YoY to ₹53 crore. The company’s operating profit, or EBITDA, surged 33% to ₹489 crore, compared to ₹368 crore in the same period last year. The EBITDA margin expanded to 27.16% from 24.44% in Q1 FY26, reflecting improved efficiency. Research and development expenses totaled ₹77 crore, representing 4% of consolidated revenue, with a focus on complex product development and regulatory filings. Gland Pharma launched four new molecules in the US during the quarter, including multi-vitamin and leucovorin calcium. The company also filed three ANDAs and received seven approvals. As of Q1 FY27, the firm has submitted 389 ANDA filings in the US, with 342 approvals and 47 pending. The CDMO business, which provides contract development and manufacturing services, contributed 50% of total revenues and recorded a 20% YoY growth.#gland_pharma #srinivas_sadu #us_market #cdmo_business #global_pharmaceutical_company
